JP2023546298A5 - - Google Patents
Info
- Publication number
- JP2023546298A5 JP2023546298A5 JP2023548543A JP2023548543A JP2023546298A5 JP 2023546298 A5 JP2023546298 A5 JP 2023546298A5 JP 2023548543 A JP2023548543 A JP 2023548543A JP 2023548543 A JP2023548543 A JP 2023548543A JP 2023546298 A5 JP2023546298 A5 JP 2023546298A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- fusion
- seq
- tgfβ superfamily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094277P | 2020-10-20 | 2020-10-20 | |
| US63/094,277 | 2020-10-20 | ||
| PCT/US2021/055646 WO2022086988A1 (en) | 2020-10-20 | 2021-10-19 | Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546298A JP2023546298A (ja) | 2023-11-01 |
| JP2023546298A5 true JP2023546298A5 (https=) | 2024-10-28 |
Family
ID=81257992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548543A Pending JP2023546298A (ja) | 2020-10-20 | 2021-10-19 | 多機能性及び多価インターロイキン－ｔｇｆ－ベータ受容体融合ポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11407814B2 (https=) |
| EP (1) | EP4232466A4 (https=) |
| JP (1) | JP2023546298A (https=) |
| KR (1) | KR20230117341A (https=) |
| CN (1) | CN116615441A (https=) |
| AU (1) | AU2021367306A1 (https=) |
| CA (1) | CA3198822A1 (https=) |
| IL (1) | IL302269A (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230117341A (ko) | 2020-10-20 | 2023-08-08 | 큐라 테라퓨틱스, 인크. | 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드 |
| CN117120075A (zh) | 2021-02-17 | 2023-11-24 | 库拉治疗股份有限公司 | 抗病原体白细胞介素-TGF-β受体融合多肽 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2449753T3 (es) | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| EP3307783B1 (en) * | 2015-06-10 | 2021-01-06 | Emory University | Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta |
| US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| US11168138B2 (en) * | 2018-03-26 | 2021-11-09 | Altor Bioscience, Llc | Anti-PDL1, IL-15 and TGF-beta receptor combination molecules |
| CN120365435A (zh) | 2018-08-30 | 2025-07-25 | 免疫生物公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| US20210061871A1 (en) | 2019-08-29 | 2021-03-04 | Nantbio, Inc. | Modified N-810 and Methods Therefor |
| KR102402276B1 (ko) | 2019-11-15 | 2022-05-26 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
| TW202233661A (zh) | 2020-10-20 | 2022-09-01 | 美商克拉治療股份有限公司 | 多功能及多價介白素-TGF-β受體融合多肽 |
| KR20230117341A (ko) | 2020-10-20 | 2023-08-08 | 큐라 테라퓨틱스, 인크. | 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드 |
| CN117120075A (zh) * | 2021-02-17 | 2023-11-24 | 库拉治疗股份有限公司 | 抗病原体白细胞介素-TGF-β受体融合多肽 |
-
2021
- 2021-10-19 KR KR1020237016944A patent/KR20230117341A/ko active Pending
- 2021-10-19 JP JP2023548543A patent/JP2023546298A/ja active Pending
- 2021-10-19 AU AU2021367306A patent/AU2021367306A1/en active Pending
- 2021-10-19 IL IL302269A patent/IL302269A/en unknown
- 2021-10-19 CN CN202180083946.7A patent/CN116615441A/zh active Pending
- 2021-10-19 CA CA3198822A patent/CA3198822A1/en active Pending
- 2021-10-19 EP EP21883712.8A patent/EP4232466A4/en active Pending
-
2022
- 2022-01-12 US US17/574,479 patent/US11407814B2/en active Active
- 2022-06-30 US US17/810,128 patent/US12258383B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2212638T3 (es) | Utilizacion de celulas tumorales en tiempo escalonado en combinacion con anticuerpos intactos para la inmunizacion. | |
| TWI403519B (zh) | Ｆｇｆ２１突變體及其用途 | |
| UA129329C2 (uk) | ЗЛИТІ БІЛКИ FLT3L-Fc | |
| JP6942051B2 (ja) | 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法 | |
| JP2023546298A5 (https=) | ||
| US6238667B1 (en) | Method of affinity cross-linking biologically active immunogenic peptides to antibodies | |
| US11352416B2 (en) | Mosaic chimeric viral vaccine particle | |
| CN107441480A (zh) | 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途 | |
| CA2257851A1 (en) | Modulators of tissue regeneration | |
| JP2023522588A5 (https=) | ||
| AU2018266562A1 (en) | Human alpha fetoprotein-specific T cell receptors and uses thereof | |
| CN104284680A (zh) | 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物 | |
| JP2023533871A5 (https=) | ||
| JP7834360B2 (ja) | 改変ブタ膵臓エラスターゼタンパク質 | |
| WO2020081786A1 (en) | Exosome-targeting bispecific antibodies | |
| KR20210104816A (ko) | Baff-r 이중특이적 t 세포 인게이저 항체 | |
| JP7822620B2 (ja) | 免疫療法のエンハンサーとして有用なｉｌ－１０／ｆｃ融合タンパク質 | |
| CA2412783C (en) | Vaccine against cancerous diseases associated with the her-2/neu oncogene | |
| CN114746106A (zh) | 通过肿瘤中使用il-7融合蛋白增加淋巴细胞数的方法 | |
| JP2023515806A5 (https=) | ||
| CN117440798A (zh) | 包含可溶性被包封多核苷酸和可电离的脂质的聚合物囊泡及其制备方法和用途 | |
| JP2024514556A5 (https=) | ||
| WO2008037225A1 (es) | Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico | |
| TW202200193A (zh) | 包含il-2蛋白及cd80蛋白的融合蛋白調配物 | |
| CN114025791A (zh) | 癌症治疗 |